Indapta Therapeutics
www.indapta.comIndapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.
Read more
Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.
Read more
Employees statistics
View all employeesPotential Decision Makers
Board of Directors
Email ****** @****.comPhone (***) ****-****Board Director
Email ****** @****.comPhone (***) ****-****Board Observer
Email ****** @****.comPhone (***) ****-****
Reach decision makers at Indapta Therapeutics
Free credits every month!
Indapta Therapeutics FAQ
United States
Biotechnology Research
